The global appetite for nicotinamide mononucleotide (NMN) has grown steadily as consumers and formulators look to the molecule for healthy-ageing applications. With demand rising, attention has turned to how NMN is actually made — and to the manufacturing routes that will define quality, cost and supply reliability for years to come.

For much of the industry's history, NMN has been produced through multi-step chemical synthesis. These routes, while well understood, typically rely on numerous reaction stages and substantial solvent inputs, followed by intensive purification to remove impurities and residual reagents. The result is a process that can be difficult to scale cleanly and that carries a heavy environmental and cost burden.

Bioprocessing offers a different path. Enzymatic synthesis uses engineered enzymes as highly selective catalysts, allowing NMN to be assembled under mild, aqueous conditions with fewer steps. Because enzymes recognise their substrates with precision, the approach tends to generate fewer unwanted by-products, which in turn simplifies downstream purification.

The practical benefits are significant. Enzymatic routes reduce solvent load compared with traditional chemical processes, supporting both sustainability goals and safer handling in the plant. Higher selectivity translates into higher purity, a critical advantage for formulators who must meet strict specifications. And by streamlining production, bioprocessing helps stabilise costs — an important consideration for commercial formulations where price volatility can disrupt supply agreements.

These advantages arrive at a moment when the wider industry is under growing scrutiny. Regulators, retailers and consumers increasingly expect ingredients to be produced with documented quality, traceability and environmental responsibility. Biocatalytic manufacturing aligns well with those expectations, which is why many producers are re-evaluating their technology platforms.

At Bioway, we see bioprocessing as central to the future of NMN supply. As a manufacturer of NMN and other high-purity ingredients, we are investing in enzymatic capabilities to deliver consistent quality, competitive cost and dependable capacity to our OEM and ODM partners worldwide.